Cyient has announced a significant share buyback program worth ₹720 crore at ₹1,125 per equity share through a tender offer, alongside releasing its Q4 financial performance and investor presentation. The engineering and technology solutions company's board approved the buyback proposal, reflecting confidence in the business fundamentals despite current market valuations.

Share Buyback and Strategic Initiatives

The board of directors approved a share buyback program for an aggregate consideration not exceeding ₹720 crore at ₹1,125 per equity share through a tender offer. According to Executive Vice-Chairman and Managing Director Krishna Bodanapu, the board believes the company's intrinsic value is not reflected in the current market price, prompting this shareholder value creation initiative.

Q4 Financial Performance - DET Segment

Cyient's Design, Engineering and Testing (DET) segment reported Q4 revenue of $163.5 million, declining 2.4% quarter-on-quarter and 1.5% year-on-year in constant currency terms. The segment maintained resilient EBIT margin at 12.4%, supported by gross margin expansion and disciplined cost management despite leadership investments and foreign exchange headwinds.

Business Unit Performance Analysis

The DET segment's business units showed mixed performance during Q4. Transportation & Mobility achieved strong growth of 4.5% quarter-on-quarter and 13.2% year-on-year in constant currency, while Networks & Infrastructure declined 3.6% quarter-on-quarter. Strategic Units faced the steepest decline at 12.4% quarter-on-quarter.

Semiconductors Segment Growth

Cyient Semiconductors delivered strong Q4 performance with revenue of $7.2 million, marking the fourth consecutive quarter of quarter-on-quarter growth at 5.4%. The segment achieved key milestones including closure of majority stake investment in Kinetic Technologies, positioning Cyient as India's largest custom chip company.

Management Outlook and Strategic Direction

Executive Director and CEO Sukamal Banerjee highlighted that the company ended the year with positive year-on-year growth in order intake across all businesses in H2. The management emphasized three strategic initiatives: market impact, technology adoption, and organizational effectiveness, with focus on AI and digital capabilities layered on domain expertise.

Cyient Limited has announced the grant of stock options to associates of the company and its subsidiaries on 23 April 2026. The Leadership, Nomination and Remuneration Committee has approved the allocation of 1,85,000 stock options under two existing employee stock option schemes.

Stock Option Grant Details

The committee has distributed the stock options across two employee stock option plans as part of the company's ongoing employee incentivization strategy.

The ASOP 2023 plan received the larger allocation with 1,07,000 options, while the ARSU 2020 plan was allocated 78,000 options. This distribution indicates the company's focus on utilizing its newer stock option framework while maintaining continuity with existing plans.

Employee Stock Option Programs

The grant covers associates from both Cyient Limited and its subsidiaries, demonstrating the company's comprehensive approach to employee equity participation across its organizational structure. The ARSU 2020 and ASOP 2023 plans represent the company's structured employee stock option schemes designed to align employee interests with shareholder value creation.

Corporate Governance

The stock option grant was formally communicated to both BSE Limited and National Stock Exchange of India Limited on 23 April 2026, ensuring compliance with regulatory disclosure requirements. The decision was executed by the Leadership, Nomination and Remuneration Committee, reflecting proper corporate governance practices in employee compensation matters.

This stock option allocation reinforces Cyient's commitment to employee retention and motivation through equity-based compensation, providing associates with opportunities to participate in the company's long-term growth and success.